MedTrace Logo

Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours

NCT04122430 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1135

Last updated 2020-10-19

No results posted yet for this study

Summary

Recent data (Srikanthan and Tran et al. JCO 2014, in press) have demonstrated that the presence of large retroperitoneal lymph node metastases on baseline staging scans (measuring \>5cm in axial dimension) are associated with significantly increased risk of venous thromboembolism in patients receiving first line chemotherapy for disseminated germ cell tumours.

This study, a G3 collaborative effort, aims to confirm these findings in a large multi-national validation cohort.

Conditions

  • Testicular Neoplasms

Interventions

OTHER

Review of Health Information

Sponsors & Collaborators

  • Royal Marsden NHS Foundation Trust

    collaborator OTHER

  • Melbourne Health

    collaborator OTHER

  • Walter and Eliza Hall Institute of Medical Research

    lead OTHER

Principal Investigators

  • Ben Tran, Medicine · Walter and Eliza Hall Institute of Medical Resaerch

Eligibility

Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2020-10-16
Completion
2020-10-16

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04122430 on ClinicalTrials.gov